Avandia to be to Studied for Prevention of Type 2 Diabetes


By: dhtest

SmithKline Beecham announced in a November 8, 2000 press release that its type 2 drug Avandia (rosiglitazone) will be the only diabetes drug studied in a first-of-its kind, multi-national, 4,000-person study to determine the impact of intensive drug therapy on preventing type 2 diabetes.

Led by Doctors Hertzel Gerstein and Salim Yusuf of McMaster University in Canada, this study, known as the DREAM trial (Diabetes Reduction Approaches with Ramipril and Rosiglitazone Medications), follows last year’s HOPE study (Heart Outcomes Prevention Evaluation), which concluded that using the ACE inhibitor Ramipril improved cardio-vascular outcomes.

DREAM is the first study to extensively evaluate the ability of intensive therapy with Avandia and/or Ramipril to prevent diabetes.

Avandia targets insulin resistance and treats this underlying cause of type 2 diabetes.

“Therefore, testing the hypothesis that Avandia should prevent or delay the progression of type 2 diabetes is a logical next step,” says David M. Stout, president-North America, SmithKline Beecham Phar-maceuticals.

“Clearly the best way to prevent the serious health consequence of diabetes is to prevent it from occurring in the first place,” says Jeff Probstfield, MD, professor of medicine and epidemiology at University of Washington Health Sciences Center and U.S. DREAM investigator.

The DREAM study will be funded by SmithKline Beecham Pharmaceuticals, King Pharmaceuticals and Aventis Pharma Canada.



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.